• Alias: MORAb-003
    • Humanized mAb immunoreactive with folate receptor-α
    • Folate receptor-α is a membrane-bound protein with upregulated expression in many cancer types, including ovarian, breast, brain, lung, and colorectal.
    • Phase 2 and 3 studies investigating farletuzumab in combination with platinum regimen in platinum-sensitive ovarian cancer
    • Recommended dose: 1.25 mg/kg or 2.5 mg/kg IV Q week in combination with chemotherapy
    • Half-life: 56 to 260 hours (increased with dose and multiple infusions)
    • Common side effects: Fatigue, nausea, drug hypersensitivity, headache, cough, exertional dyspnea
    (Konner et al., 2010)
    Other topics in Targeted and Immunotherapy Agents